Terms: = Germ cell tumor AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5
198 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
3. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
[TBL] [Abstract] [Full Text] [Related]
4. SOMATIC DEFICIENT MISMATCH REPAIR ASSESSED BY IMMUNOHISTOCHEMISTRY AND CLINICAL FEATURES IN BRAZILIAN GLIOBLASTOMA PATIENTS.
Yamada CAF; Malheiros SMF; Do Amaral LLF; Lancellotti CLP
Exp Oncol; 2023 Dec; 45(3):297-311. PubMed ID: 38186025
[TBL] [Abstract] [Full Text] [Related]
5. Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant β-Catenin Expression: A Case Expanding the Histologic Spectrum of β-Catenin Activated Gynecologic Neoplasia.
Xu J; Weisman PS
Int J Gynecol Pathol; 2024 May; 43(3):302-307. PubMed ID: 37922945
[TBL] [Abstract] [Full Text] [Related]
6. Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G; Szőke P; Bátai B; Nagy T; Papp G; Kránitz N; Rajnai H; Reiniger L; Bödör C; Scheich B
Sci Rep; 2023 Oct; 13(1):18436. PubMed ID: 37891325
[TBL] [Abstract] [Full Text] [Related]
7. Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study.
Kaneko M; Nakashima M; Sugiura K; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Osawa S; Tatsuta K; Kurachi K; Baba S; Iwashita Y; Arai T; Sugimura H; Maekawa M; Sugimoto K; Iwaizumi M
Medicine (Baltimore); 2023 Sep; 102(38):e35022. PubMed ID: 37746995
[TBL] [Abstract] [Full Text] [Related]
8. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
[TBL] [Abstract] [Full Text] [Related]
9. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract] [Full Text] [Related]
10. Branchioma with a nested/organoid morphology: molecular profiling of a distinctive potentially misleading variant and reappraisal of potential relationship to CD34-positive/Rb1-deficient tumors of the neck.
Baněčková M; Michal M; Vaněček T; Grossman P; Nikolov DH; Včelák R; Žalud R; Michal M; Agaimy A
Virchows Arch; 2023 Oct; 483(4):541-548. PubMed ID: 37401932
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
12. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract] [Full Text] [Related]
13. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
14. Mixed adenoneuroendocrine carcinoma of the gallbladder.
Wang Q; Li L; Li J; Fan W
Rev Esp Enferm Dig; 2024 Jan; 116(1):48-49. PubMed ID: 37073699
[TBL] [Abstract] [Full Text] [Related]
15. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract] [Full Text] [Related]
16. Renal cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
[TBL] [Abstract] [Full Text] [Related]
17. germline pathogenic variants in patients with early-onset neuroendocrine neoplasms.
Riechelmann RP; Donadio MDS; Jesus VHF; de Carvalho NA; Santiago KM; Barros MJ; Lopes L; Oliveira Dos Santos G; Nirvana Formiga M; Carraro DM; Torrezan GT
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36947458
[TBL] [Abstract] [Full Text] [Related]
18. Whole-exome sequencing reveals genetic variants in low-risk and high-risk neuroblastoma.
Altun Z; Yuan H; Baran B; Aktaş S; Sönmez EE; Küçük C; Olgun N
Gene; 2023 Apr; 860():147233. PubMed ID: 36736507
[TBL] [Abstract] [Full Text] [Related]
19. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract] [Full Text] [Related]
20. Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes.
Zhang H; Jiang D; Meng E; Zhao M; Niu B
Immunotherapy; 2023 Jan; 15(1):17-25. PubMed ID: 36647794
[TBL] [Abstract] [Full Text] [Related]
[Next]
